Formed by a proprietary particle engineering technology, patented large surface area microparticles (LSAMs) of pure drug are suspended at time of use for tumor-directed therapy via intratumoral, intraperitoneal, instillation, inhalation, and other routes of local administration where the particles are retained at the disease site as a depot continuously releasing drug molecules as the particles dissolve over time.


Patented large surface area microparticles (LSAMs) of pure drug are locally delivered directly to the site of disease.

Particles versus

LSAMs become entrapped at the disease site whereas drug in solution leaks out by simple diffusion.

SCP Technology

The proprietary supercritical precipitation (SCP) technology forms stable LSAMs of pure drug that are suspended in a saline-based dilution fluid just prior to local administration.

IP Portfolio

A composition of matter patent protects the regulatory specifications of the LSAMs forming the foundation of an extensive global intellectual property portfolio.